阿托西班在体外受精-胚胎移植中的研究及应用进展

Research and Application Progress of Atosiban in Vitro Fertilization-Embryo Transfer

胚胎移植是体外受精-胚胎移植技术的关键阶段,过度的子宫收缩可降低子宫内膜容受性,导致胚胎移植失败。阿托西班是缩宫素/血管升压素V1A受体拮抗剂,具有子宫特异性,可通过抑制子宫收缩提高胚胎移植的成功率,在辅助生殖领域具有广阔的应用前景。阿托西班可提高新鲜胚胎移植以及冻融胚胎移植的成功率,同时对于囊胚移植以及反复移植失败者也可发挥一定作用。此外,移植前单次小剂量应用阿托西班可能优于大剂量、全程给药。阿托西班在辅助生殖领域的应用价值仍需未来进一步研究验证。

Embryo transfer is the key stage of in vitro fertilization-embryo transfer,and excessive uterine contractions can reduce endometrial receptivity,resulting in embryo transfer failure.Atosiban is an oxytocin/vasopressin V1A receptor antagonist with uterine specificity,which can improve the success rate of embryo transfer and has a broad prospect in the field of assisted reproduction.Atosiban can improve the success rate of fresh embryo transfer and frozen-thawed embryo transfer,and it also plays a certain role in blastocyst transfer and repeated implantation failure.Besides,a single small dose of atosiban before transplantation is likely to be better than a large dose and a whole course of administration.However,the application value of atosiban in assisted reproduction still needs to be verified by more studies in the future.